Macrophages promote polycystic kidney disease progression

Kidney International

Volumn 83, Issue 5, 2013, Pages 855-864

  Swenson Fields, Katherine I ^a,b   Vivian, Carolyn J ^a,b   Salah, Sally M ^a,b   Peda, Jacqueline D ^a,b   Davis, Bradley M ^b   Van Rooijen, Nico ^c   Wallace, Darren P ^a,b   Fields, Timothy A ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

clodronate; M2 macrophage; polycystic kidney disease

Indexed keywords

CD163 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; EPITHELIUM CELL; HUMAN; HUMAN CELL; KIDNEY POLYCYSTIC DISEASE; KIDNEY TUBULE CELL; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 84877038190     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.446     Document Type: Article

References (38)

1. Duffield JS. Macrophages and immunologic inflammation of the kidney. Semin Nephrol 2010; 30: 234-254.
2. Eardley K, Cockwell P. Macrophages and progressive tubulointerstitial disease. Kidney Int 2005; 68: 437-455.
3. Duffield JS. Macrophages in kidney repair and regeneration. J Am Soc Nephrol 2011; 22: 199-201.
4. Lee S, Huen S, Nishio H et al. Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol 2011; 22: 317-326.
5. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009; 27: 451-483.
6. Murray PJ, Wynn TA. Obstacles and opportunities for understanding macrophage polarization. J Leukoc Biol 2011; 89: 557-563.
7. Anders HJ, Ryu M. Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int 2011; 80: 915-925.
8. Ricardo SD, van Goor H, Eddy AA. Macrophage diversity in renal injury and repair. J Clin Invest 2008; 118: 3522-3530.
9. Fujiu K, Manabe I, Nagai R. Renal collecting duct epithelial cells regulate inflammation in tubulointerstitial damage in mice. J Clin Invest 2011; 121: 3425-3441.
10. Lin SL, Castano AP, Nowlin BT et al. Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J Immunol 2009; 183: 6733-6743.
11. Grantham JJ, Mulamalla S, Swenson-Fields KI. Why kidneys fail in autosomal dominant polycystic kidney disease. Nat Rev Nephrol 2011; 7: 556-566.
12. Sweeney WE Jr., Avner ED. Molecular and cellular pathophysiology of autosomal recessive polycystic kidney disease (ARPKD). Cell Tissue Res 2006; 326: 671-685.
13. Grantham JJ. Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: a systems biology approach. Kidney Int 2003; 64: 1157-1162.
14. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007; 369: 1287-1301.
15. Renal Data System US. Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2011.
16. Prasad S, McDaid JP, Tam FW et al. Pkd2 dosage influences cellular repair responses following ischemia-reperfusion injury. Am J Pathol 2009; 175: 1493-1503.
17. Zeier M, Fehrenbach P, Geberth S et al. Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int 1992; 42: 1259-1265.
18. Karihaloo A, Koraishy F, Huen SC et al. Macrophages promote cyst growth in polycystic kidney disease. J Am Soc Nephrol 2011; 22: 1809-1814.
19. Mrug M, Zhou J, Woo Y et al. Overexpression of innate immune response genes in a model of recessive polycystic kidney disease. Kidney Int 2008; 73: 63-76.
20. Fry JL Jr., Koch WE, Jennette JC et al. A genetically determined murine model of infantile polycystic kidney disease. J Urol 1985; 134: 828-833.
21. Hou X, Mrug M, Yoder BK et al. Cystin, a novel cilia-associated protein, is disrupted in the cpk mouse model of polycystic kidney disease. J Clin Invest 2002; 109: 533-540.
22. Preminger GM, Koch WE, Fried FA et al. Murine congenital polycystic kidney disease: a model for studying development of cystic disease. J Urol 1982; 127: 556-560.
23. Yoder BK, Hou X, Guay-Woodford LM. The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J Am Soc Nephrol 2002; 13: 2508-2516.
24. Gown AM, Tsukada T, Ross R. Human atherosclerosis. II. Immunocytochemical analysis of the cellular composition of human atherosclerotic lesions. Am J Pathol 1986; 125: 191-207.
25. Mantovani A, Sozzani S, Locati M et al. Macrophage polarization: tumorassociated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-555.
26. Van Gorp H, Delputte PL, Nauwynck HJ. Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. Mol Immunol 2010; 47: 1650-1660.
27. Ibelgaufts H. Cytokines and Cells Online Pathfinder Encyclopedia. http://www.copewithcytokines.org, 2010.
28. Mangoo-Karim R, Uchic ME, Grant M et al. Renal epithelial fluid secretion and cyst growth: the role of cyclic AMP. FASEB J 1989; 3: 2629-2632.
29. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994; 174: 83-93.
30. Van Rooijen N, Sanders A, Van den Berg TK. Apoptosis of macrophages induced by liposome-mediated intracellular delivery of clodronate and propamidine. J Immunol Methods 1996; 193: 93-99.
31. Gerdes J, Lemke H, Baisch H et al. Cell cycle analysis of a cell proliferationassociated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133: 1710-1715.
32. Cowley BD Jr., Ricardo SD, Nagao S et al. Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats. Kidney Int 2001; 60: 2087-2096.
33. Zheng D, Wolfe M, Cowley BD Jr. et al. Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2003; 14: 2588-2595.
34. Lanoix J, D'Agati V, Szabolcs M et al. Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease (ADPKD). Oncogene 1996; 13: 1153-1160.
35. Lin SL, Li B, Rao S et al. Macrophage Wnt7b is critical for kidney repair and regeneration. Proc Natl Acad Sci USA 2010; 107: 4194-4199.
36. Patel V, Li L, Cobo-Stark P et al. Acute kidney injury and aberrant planar cell polarity induce cyst formation in mice lacking renal cilia. Hum Mol Genet 2008; 17: 1578-1590.
37. Takakura A, Contrino L, Zhou X et al. Renal injury is a third hit promoting rapid development of adult polycystic kidney disease. Hum Mol Genet 2009; 18: 2523-2531.
38. Happe H, Leonhard WN, van der Wal A et al. Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways. Hum Mol Genet 2009; 18: 2532-2542.